148 related articles for article (PubMed ID: 27823565)
21. 1-(3-Deoxy-3-fluoro-beta-d-glucopyranosyl) pyrimidine derivatives as inhibitors of glycogen phosphorylase b: Kinetic, crystallographic and modelling studies.
Tsirkone VG; Tsoukala E; Lamprakis C; Manta S; Hayes JM; Skamnaki VT; Drakou C; Zographos SE; Komiotis D; Leonidas DD
Bioorg Med Chem; 2010 May; 18(10):3413-25. PubMed ID: 20430629
[TBL] [Abstract][Full Text] [Related]
22. The structure of brain glycogen phosphorylase-from allosteric regulation mechanisms to clinical perspectives.
Mathieu C; Dupret JM; Rodrigues Lima F
FEBS J; 2017 Feb; 284(4):546-554. PubMed ID: 27782369
[TBL] [Abstract][Full Text] [Related]
23. Advances in glycogen phosphorylase inhibitor design.
Oikonomakos NG; Somsák L
Curr Opin Investig Drugs; 2008 Apr; 9(4):379-95. PubMed ID: 18393105
[TBL] [Abstract][Full Text] [Related]
24. Sensitivity of glycogen phosphorylase isoforms to indole site inhibitors is markedly dependent on the activation state of the enzyme.
Freeman S; Bartlett JB; Convey G; Hardern I; Teague JL; Loxham SJ; Allen JM; Poucher SM; Charles AD
Br J Pharmacol; 2006 Nov; 149(6):775-85. PubMed ID: 17016495
[TBL] [Abstract][Full Text] [Related]
25. Inhibitory properties of 1,4-dideoxy-1,4-imino-d-arabinitol (DAB) derivatives acting on glycogen metabolising enzymes.
Díaz-Lobo M; Concia AL; Gómez L; Clapés P; Fita I; Guinovart JJ; Ferrer JC
Org Biomol Chem; 2016 Sep; 14(38):9105-9113. PubMed ID: 27714243
[TBL] [Abstract][Full Text] [Related]
26. Computation as a tool for glycogen phosphorylase inhibitor design.
Hayes JM; Leonidas DD
Mini Rev Med Chem; 2010 Oct; 10(12):1156-74. PubMed ID: 20716053
[TBL] [Abstract][Full Text] [Related]
27. Recent advances in the allosteric inhibition of glycogen phosphorylase.
Loughlin WA
Mini Rev Med Chem; 2010 Oct; 10(12):1139-55. PubMed ID: 20716052
[TBL] [Abstract][Full Text] [Related]
28. Glucose-based spiro-isoxazolines: a new family of potent glycogen phosphorylase inhibitors.
Benltifa M; Hayes JM; Vidal S; Gueyrard D; Goekjian PG; Praly JP; Kizilis G; Tiraidis C; Alexacou KM; Chrysina ED; Zographos SE; Leonidas DD; Archontis G; Oikonomakos NG
Bioorg Med Chem; 2009 Oct; 17(20):7368-80. PubMed ID: 19781947
[TBL] [Abstract][Full Text] [Related]
29. Glucose-derived spiro-isoxazolines are anti-hyperglycemic agents against type 2 diabetes through glycogen phosphorylase inhibition.
Goyard D; Kónya B; Chajistamatiou AS; Chrysina ED; Leroy J; Balzarin S; Tournier M; Tousch D; Petit P; Duret C; Maurel P; Somsák L; Docsa T; Gergely P; Praly JP; Azay-Milhau J; Vidal S
Eur J Med Chem; 2016 Jan; 108():444-454. PubMed ID: 26708111
[TBL] [Abstract][Full Text] [Related]
30. Synthesis of (benzimidazol-2-yl)aniline derivatives as glycogen phosphorylase inhibitors.
Galal SA; Khattab M; Andreadaki F; Chrysina ED; Praly JP; Ragab FAF; El Diwani HI
Bioorg Med Chem; 2016 Nov; 24(21):5423-5430. PubMed ID: 27624527
[TBL] [Abstract][Full Text] [Related]
31. Glycogen phosphorylase as a molecular target for type 2 diabetes therapy.
Oikonomakos NG
Curr Protein Pept Sci; 2002 Dec; 3(6):561-86. PubMed ID: 12470212
[TBL] [Abstract][Full Text] [Related]
32. Terpenoids. III: Synthesis and biological evaluation of 23-hydroxybetulinic acid derivatives as novel inhibitors of glycogen phosphorylase.
Zhu P; Bi Y; Xu J; Li Z; Liu J; Zhang L; Ye W; Wu X
Bioorg Med Chem Lett; 2009 Dec; 19(24):6966-9. PubMed ID: 19889536
[TBL] [Abstract][Full Text] [Related]
33. Probing the β-pocket of the active site of human liver glycogen phosphorylase with 3-(C-β-d-glucopyranosyl)-5-(4-substituted-phenyl)-1, 2, 4-triazole inhibitors.
Kyriakis E; Solovou TGA; Kun S; Czifrák K; Szőcs B; Juhász L; Bokor É; Stravodimos GA; Kantsadi AL; Chatzileontiadou DSM; Skamnaki VT; Somsák L; Leonidas DD
Bioorg Chem; 2018 Apr; 77():485-493. PubMed ID: 29454281
[TBL] [Abstract][Full Text] [Related]
34. 3'-axial CH2 OH substitution on glucopyranose does not increase glycogen phosphorylase inhibitory potency. QM/MM-PBSA calculations suggest why.
Manta S; Xipnitou A; Kiritsis C; Kantsadi AL; Hayes JM; Skamnaki VT; Lamprakis C; Kontou M; Zoumpoulakis P; Zographos SE; Leonidas DD; Komiotis D
Chem Biol Drug Des; 2012 May; 79(5):663-73. PubMed ID: 22296957
[TBL] [Abstract][Full Text] [Related]
35. Glycogen phosphorylase inhibitors: a free energy perturbation analysis of glucopyranose spirohydantoin analogues.
Archontis G; Watson KA; Xie Q; Andreou G; Chrysina ED; Zographos SE; Oikonomakos NG; Karplus M
Proteins; 2005 Dec; 61(4):984-98. PubMed ID: 16245298
[TBL] [Abstract][Full Text] [Related]
36. Naturally occurring pentacyclic triterpenes as inhibitors of glycogen phosphorylase: synthesis, structure-activity relationships, and X-ray crystallographic studies.
Wen X; Sun H; Liu J; Cheng K; Zhang P; Zhang L; Hao J; Zhang L; Ni P; Zographos SE; Leonidas DD; Alexacou KM; Gimisis T; Hayes JM; Oikonomakos NG
J Med Chem; 2008 Jun; 51(12):3540-54. PubMed ID: 18517260
[TBL] [Abstract][Full Text] [Related]
37. Selective photoregulation of the activity of glycogen synthase and glycogen phosphorylase, two key enzymes in glycogen metabolism.
Díaz-Lobo M; Garcia-Amorós J; Fita I; Velasco D; Guinovart JJ; Ferrer JC
Org Biomol Chem; 2015 Jul; 13(26):7282-8. PubMed ID: 26055498
[TBL] [Abstract][Full Text] [Related]
38. Physiological control of liver glycogen metabolism: lessons from novel glycogen phosphorylase inhibitors.
Agius L
Mini Rev Med Chem; 2010 Oct; 10(12):1175-87. PubMed ID: 20716056
[TBL] [Abstract][Full Text] [Related]
39. New inhibitors of glycogen phosphorylase as potential antidiabetic agents.
Somsák L; Czifrák K; Tóth M; Bokor E; Chrysina ED; Alexacou KM; Hayes JM; Tiraidis C; Lazoura E; Leonidas DD; Zographos SE; Oikonomakos NG
Curr Med Chem; 2008; 15(28):2933-83. PubMed ID: 19075645
[TBL] [Abstract][Full Text] [Related]
40. From structure--based to knowledge--based drug design through x-ray protein crystallography: sketching glycogen phosphorylase binding sites.
Chrysina ED; Chajistamatiou A; Chegkazi M
Curr Med Chem; 2011; 18(17):2620-9. PubMed ID: 21568887
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
